Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ADILW Adial Pharmaceuticals Inc C/ Wts 31/07/2023 (To Pur Com)
0.037-0.006-13.95%
Close
03/23 16:00 ET
High
0.037
Open
0.037
Turnover
21.00
Low
0.037
Pre Close
0.043
Volume
555.00
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder
The Keswick Group is led by experienced pharmaceutical business development executive, Tony GoodmanCHARLOTTESVILLE, Va., March 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL;
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th
CHARLOTTESVILLE, Va., March 08, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the
Adial Pharmaceuticals Schedules Business Update Conference Call
CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the
Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
CHARLOTTESVILLE, Va., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing
Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering
CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the
Adial Pharmaceuticals Confirms Scheduling of Meetings With FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder
Type C meeting with FDA set for Second Quarter Plans in Place to Meet with Multiple Regulatory Agencies Throughout Europe CHARLOTTESVILLE, Va., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceutical
Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley Po
Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to President
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 - Chronic Constrictive Injury Model (Rat) PNV-5030 - Chronic Constrictive Injury Model (Rat)CHARLOTTESVILLE, Va.
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data With Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis
PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model PNV-6005 - DSS-induced Ulcerative Colitis Model (Mice) PNV-6005 - DSS-induced Ulcerative Colitis Mod
